Sanai, Faisal M <br/><br/>
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.  [electronic resource] 

 -  Liver international : official journal of the International Association for the Study of the Liver  08 2018 
 - 1395-1401 p.  digital 
<br/><br/> Publication Type: Journal Article; Observational Study 
<br/><br/><label>ISSN: </label>1478-3231 
<br/><br/><label>Standard No.: </label>10.1111/liv.13674  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Adult<br/>Anilides--therapeutic use<br/>Antiviral Agents--therapeutic use<br/>Carbamates--therapeutic use<br/>Cohort Studies<br/>Cyclopropanes<br/>Drug Therapy, Combination<br/>Female<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--complications<br/>Humans<br/>Lactams, Macrocyclic<br/>Liver Cirrhosis--virology<br/>Macrocyclic Compounds--therapeutic use<br/>Male<br/>Middle Aged<br/>Proline--analogs & derivatives<br/>Registries<br/>Renal Insufficiency, Chronic--complications<br/>Ribavirin--therapeutic use<br/>Ritonavir--therapeutic use<br/>Saudi Arabia<br/>Sulfonamides--therapeutic use<br/>Sustained Virologic Response<br/>Uracil--analogs & derivatives<br/>Valine